Exth-36. Shifting From Epigenetics To The Epichaperome: Hsp90 As A Therapeutic Target For H3K27M Diffuse Midline Glioma (Dmg)

Stefanie-Grace Sbergio,Sanja Pajovic,Arun Anguraj Vadivel,Jun Watanabe,Javal Sheth,Laura Canty,Gabriela Chiosis,Mark Nitz,Rintaro Hashizume,Cynthia Hawkins

DOI: https://doi.org/10.1093/neuonc/noae165.0967

2024-11-29

Neuro-Oncology

Abstract:Diffuse midline gliomas (DMG) are lethal pediatric brain tumours, the majority of which have truncal histone (H3K27M) mutations. To investigate cellular vulnerabilities of histone mutant cells we generated oligodendrocyte precursor cells (OPC) isogenic cell lines and performed a high-throughput synthetic lethality drug screen (2400 small molecules). This identified HSP90 inhibitors as a potential therapeutic option for H3K27M DMG. We hypothesize that epichaperome HSP90 inhibitors present a new therapeutic approach targeting multiple aspects of DMG oncogenicity. HSP90 inhibitors, PU-H71 and PU-HZ151, effectively reduced viability of DMG lines in vitro in the low nanomolar range and result in caspase mediated cell death (p<0.0001 1 uM, p<0.05 500 nM, n=6). PU-HZ151 treated mice had a survival benefit vs control mice injected with orthotopic DMG xenografts (p=0.0012). In diseased cells, activated HSP90 forms a scaffold defined as the epichaperome. To unravel the molecular mechanisms of epichaperome inhibition in DMG cells, we performed epichaperomics – a pull down of epichaperome HSP90 with co-chaperones and clients followed by LC-MS/MS analysis. We identified an interactome enriched with proteins involved in cell cycling, RAS/MAPK signaling, immune response, and metabolic reprogramming. Proteomic and phosphoproteomic profiling of DMG cells post-PU-HZ151 treatment provided insights into the direct downstream effects critical for maintaining DMG viability, identified functional vulnerabilities primed by epichaperome inhibition including downregulation of cell cycling, and upregulation of HSF1 mediated cellular response to stress. In silico screening and kinase enrichment analysis highlighted CSNK2A1 as a top active kinase in DMG cells following PU-HZ151 treatment. To enhance the therapeutic efficacy of epichaperome inhibition, we employed the CSNK2A1 kinase inhibitor, CX-4945, in combination with PU-HZ151, resulting in the effective ablation of DMG patient cells in vitro. These data highlight the potential of epichaperome inhibitors for DMG treatment, as they target multiple DMG oncogenic pathways.

oncology,clinical neurology